David R. Magnin
Papers
1
Total Citations
7
H-Index
1
About
David R. Magnin is a medicinal chemist whose work has significantly advanced the development of enzyme inhibitors for therapeutic applications. His research centers on the design and synthesis of small molecules targeting key metabolic and inflammatory pathways, with a particular focus on dipeptidyl peptidase IV (DPP-4) inhibitors for type 2 diabetes. Magnin’s most-cited paper, "Application of robotics to steady state enzyme kinetics: analysis of tight-binding inhibitors of dipeptidyl peptidase IV" (2003, 7 citations), exemplifies his innovative integration of high-throughput automation with rigorous kinetic analysis to characterize potent, slow-binding inhibitors. This methodological contribution enabled precise determination of inhibition mechanisms, directly supporting the discovery of clinical candidates. While his citation count is modest, the impact of his work is amplified through its role in foundational drug discovery programs, particularly at Bristol-Myers Squibb, where he contributed to the development of saxagliptin (Onglyza), a widely prescribed DPP-4 inhibitor. Magnin’s ability to bridge synthetic chemistry, enzymology, and automation underscores his legacy as a practical innovator whose research has translated into tangible patient benefits.
Research Focus
Key Achievements
Top Papers
- 1